Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study—a randomised controlled trial

BACKGROUND: The optimal use of various therapeutic combinations for moderate/severe chronic obstructive pulmonary disease (COPD) is unclear. The GLISTEN trial compared the efficacy of two long-acting anti-muscarinic antagonists (LAMA), when combined with an inhaled corticosteroid (ICS) and a long-ac...

Descripción completa

Detalles Bibliográficos
Autores principales: Frith, Peter A, Thompson, Philip J, Ratnavadivel, Rajeev, Chang, Catherina L, Bremner, Peter, Day, Peter, Frenzel, Christina, Kurstjens, Nicol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Chronic Obstructive Pulmonary Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453631/
https://www.ncbi.nlm.nih.gov/pubmed/25841237
http://dx.doi.org/10.1136/thoraxjnl-2014-206670

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453631/
https://www.ncbi.nlm.nih.gov/pubmed/25841237
http://dx.doi.org/10.1136/thoraxjnl-2014-206670

Ejemplares similares